James reimann, Ph.D.

Dynamic Coaching for Life Science Leaders

CoCreative Insights LLC

In July 2025 James completed a 30-year career as a Biostatistician and Data Science leader at Genentech/Roche to start his own company, CoCreative Insights, which provides dynamic leadership coaching to executives, managers, and high-potential individual contributors working in life science companies. 

James provides collaborative and creative coaching in both the professional and personal domains, including executive coaching, leadership/career coaching, and coaching through life transitions. Coaching is a forward-looking, collaborative exploration between coach and client, that empowers the client to clarify personal goals, overcome obstacles, and make meaningful progress.

James was raised in South Australia and completed his undergraduate studies at the University of Adelaide.  He came to California in 1990 to pursue PhD studies in Statistics at the University of California at Berkeley, during which he first worked for Genentech as a Summer Intern.  James joined Genentech in 1994 and spent his first 5 years supporting Early-Development for experimental therapies for various non-Oncology therapeutic areas. 

James joined the Avastin project in 2000 as was responsible for the first Phase III study of Avastin in breast cancer and later served as the Development filing team leader for the US BLA submission in colorectal cancer.  He then led the biostatistics group supporting the HER projects (Herceptin, Perjeta, and Tarceva) including the US approval for Tarceva in lung cancer.  He then took on positions of increasing responsibility, including Development Team Leader for Herceptin, Genentech head for Avastin Biostatistics, and Global Head of Oncology Biostatistics.

James also gained experience leading other Biometrics functions, including overseeing the Patient-Centered Outcome Research group (which develops, applies, and analyzes patient-centered endpoints in clinical trials) and leading the Roche global Clinical Data Management for 4.5 years.